Tag: next generation immunotherapies market demand

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Next Generation Immunotherapies Market Value Expansion And Long-Term Growth Outlook

The market for next-generation immunotherapies has experienced significant expansion lately, projecting an increase from $150.12 billion in 2025 to $168.33 billion in 2026, reflecting a compound annual growth rate of 12.1%. Factors behind this historic growth trajectory include the escalating worldwide incidence of cancer, the initial triumphs observed with immune checkpoint inhibitors, augmented investments in oncology research and development, the successful regulatory approval of monoclonal antibodies, and a heightened understanding of immuno-oncology treatments.

The market for next-generation immunotherapies is poised for substantial expansion in the coming years, projected to reach $262.82 billion by 2030, reflecting a compound annual growth rate of 11.8%. This anticipated growth trajectory is underpinned by several key factors, including continuous innovation in antibody engineering techniques, the broadening scope of immunotherapy applications beyond cancer treatment, a rise in the number of approved antibody-drug conjugate therapies, the increasing utilization of biomarker-guided treatment strategies, and a growing patient preference for enduring and long-term therapeutic solutions. Within this forecast period, several significant trends are expected to shape the market landscape, such as the proliferation of combination immunotherapy approaches, advancements and wider implementation of personalized cancer vaccines, a greater uptake of bispecific antibodies, an intensified effort to mitigate immune-related side effects, and a surge in clinical trial investigations for solid tumor treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

Next Generation Immunotherapies Market Demand Drivers Creating New Revenue Opportunities

The escalating incidence of cancer is poised to significantly fuel the expansion of the next-generation immunotherapies market. Cancer, a complex group of diseases defined by the aberrant proliferation and dissemination of faulty cells, is becoming more common due to demographic shifts towards older populations, evolving lifestyle habits, environmental influences, and enhanced diagnostic capabilities. Next-generation immunotherapies represent cutting-edge, precise therapeutic approaches designed to bolster the body’s natural defenses against malignant cells, thereby promising superior efficacy, sustained impact, and tailored treatment plans. Illustrating this trend, data released in July 2024 by Cancer Research UK indicated that cancer diagnoses in the United Kingdom are anticipated to rise across most forms between 2023-2025 and 2038-2040, with increases varying from under 1% for breast cancer to as much as 50% for eye cancer, though certain cancers, like lung cancer (a 2% decrease) and mesothelioma (a 27% decrease), are expected to experience a decline. Consequently, the escalating burden of cancer is directly stimulating the growth trajectory of the next-generation immunotherapies sector.

Next Generation Immunotherapies Market Segment Analysis Highlighting Growth Areas

The next generation immunotherapies market covered in this report is segmented –

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors

2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies

2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs

3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications

4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

Next Generation Immunotherapies Market Trends Driving Strategic Industry Expansion

Leading entities within the burgeoning next-generation immunotherapies sector are dedicating resources to pioneering treatments, including CAR T-cell therapy, aimed at combating oncological conditions, autoimmune disorders, and infectious diseases. CAR T-cell therapy involves the genetic modification of a patient’s T cells, a crucial component of the immune system, to incorporate chimeric antigen receptors (CARs). Illustrating this advancement, Immuneel Therapeutics Private Limited, an Indian enterprise specializing in cell and gene therapies, introduced Qartemi in January 2025, marking it as the inaugural CAR T-cell therapy developed in India. This groundbreaking treatment targets adult B-cell non-Hodgkin lymphoma by re-engineering a patient’s own immune cells to specifically identify and eliminate malignant cells, presenting a highly potent and individualized therapeutic avenue. The therapy offers a significant beacon of hope for individuals unresponsive to standard treatments, additionally presenting a more cost-effective alternative to comparable international therapies.

Next Generation Immunotherapies Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

Access The Complete Next Generation Immunotherapies Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

Next Generation Immunotherapies Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the next-generation immunotherapies market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Next Generation Immunotherapies Market By 2030 Based On Its 2026 Value?

The next generation immunotherapies market size has experienced rapid expansion in recent years. This market is projected to expand from $150.12 billion in 2025 to reach $168.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. Historically, this growth can be linked to factors such as rising global cancer prevalence, the early success of immune checkpoint inhibitors, increased oncology r&d investments, regulatory approvals of monoclonal antibodies, and growing awareness of immuno-oncology therapies.

The market for next generation immunotherapies is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a value of $262.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This projected growth during the forecast period stems from several factors, including breakthroughs in next-generation antibody engineering, the expansion of applications beyond cancer treatment, the increasing approval of ADC-based therapies, an increase in biomarker-guided treatment choices, and a growing need for therapies that offer lasting and sustained effects. Key trends anticipated for this period encompass the broadening of combination immunotherapy approaches, an increase in personalized cancer vaccines, a growing uptake of bispecific antibodies, a heightened emphasis on mitigating immune-related side effects, and more rapid clinical trial progress for solid tumors.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

What Market Drivers Are Helping Shape The Next Generation Immunotherapies Market Expansion?

The growing occurrence of cancer is projected to drive the expansion of the next-generation immunotherapies market. Cancer involves a collection of illnesses marked by the uncontrolled multiplication and dispersion of irregular cells within the body. The widespread presence of cancer stems from factors such as an aging demographic, shifts in lifestyle, environmental exposures, and enhanced diagnostic techniques. Next-generation immunotherapies deliver advanced, targeted treatments designed to strengthen the body’s immune defense against cancer, providing improved efficacy, lasting effects, and tailored approaches. For instance, in July 2024, projections from Cancer Research UK, a UK-based cancer charity, indicated that cancer incidence rates in the United Kingdom are expected to climb for most types between 2023-2025 and 2038-2040, with increases varying from less than 1% for breast cancer to 50% for eye cancer. Conversely, a smaller number of cancers are predicted to decrease, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the rising prevalence of cancer is fueling the growth of the next-generation immunotherapies market.

Which Segment Divisions Form The Structure Of The Next Generation Immunotherapies Market?

The next generation immunotherapies market covered in this report is segmented –

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors

2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies

2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs

3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications

4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

Which Trends Are Influencing The Direction Of The Next Generation Immunotherapies Market?

Leading companies in the next generation cancer diagnostics market are concentrating on developing innovative solutions, such as artificial intelligence-driven multi-modal diagnostic platforms, to improve early detection, personalized treatment, and clinical decision-making. These advanced systems utilize artificial intelligence to integrate and analyze various biological data types, including genomic, proteomic, imaging, and clinical information, thereby offering more accurate and individualized cancer detection and diagnosis. For example, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, introduced OncoIncytes, a multi-modal cancer diagnostic platform specifically designed for precision oncology. This platform combines different data types, such as circulating tumor DNA, single-cell circulating tumor cells, RNA information, and detailed protein profiles of 150 proteins at the single-cell level. By using a 1080-gene panel powered by AI and machine learning, OncoIncytes delivers highly sensitive and specific insights that enhance clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform allows for personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible through OneCell’s proprietary iDiscover application from a CLIA-certified laboratory.

Which Companies Form The Competitive Landscape Of The Next Generation Immunotherapies Market?

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

Access The Complete Next Generation Immunotherapies Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

Which Geographic Region Represents The Largest Next Generation Immunotherapies Market Share?

North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Next Generation Immunotherapies Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp

Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Breast Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Oncology Companion Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Next Generation Immunotherapies Market During The Forecast Period?

The next generation immunotherapies market size has expanded quickly in recent years. It is forecast to increase from $150.12 billion in 2025 to $168.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.1%. The expansion observed historically can be attributed to factors such as increasing global cancer prevalence, the initial accomplishments of immune checkpoint inhibitors, augmented investments in oncology research and development, regulatory authorizations of monoclonal antibodies, and heightened awareness of immuno-oncology therapies.

The next generation immunotherapies market size is anticipated to undergo significant expansion in the coming years, projected to reach $262.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. This growth during the forecast period is attributable to breakthroughs in next-generation antibody engineering, the expansion of applications beyond oncology, an increasing number of approvals for ADC-based therapies, the advancement of biomarker-driven treatment selection, and a growing demand for durable and long-lasting therapies. Prominent trends for the forecast period include the broader adoption of combination immunotherapy regimens, the rise of personalized cancer vaccines, the increasing use of bispecific antibodies, a heightened focus on reducing immune-related adverse events, and accelerated clinical trial activity targeting solid tumors.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

What Key Factors Are Shaping The Next Generation Immunotherapies Market Landscape?

The increasing occurrence of cancer is projected to stimulate the growth of the next-generation immunotherapies market moving forward. Cancer refers to a collection of illnesses defined by the uncontrolled proliferation and dispersion of atypical cells within the body. The widespread presence of cancer stems from factors such as an aging global populace, shifts in lifestyle, environmental exposures, and enhanced detection methodologies. Next-generation immunotherapies offer sophisticated, precise treatments that boost the body’s immune reaction against cancer, leading to superior efficacy, endurance, and tailored care. For example, in July 2024, projections released by Cancer Research UK, a UK-based cancer charity, indicated that cancer incidence rates in the United Kingdom are expected to climb for most types between 2023-2025 and 2038-2040, with increases ranging from less than 1% for breast cancer to 50% for eye cancer, while a smaller subset of cancers is anticipated to decline, seeing reductions from 2% for lung cancer to 27% for mesothelioma. Hence, the rising prevalence of cancer is fostering the expansion of the next-generation immunotherapies market.

What Segment Categories Shape The Next Generation Immunotherapies Market Segment Landscape?

The next generation immunotherapies market covered in this report is segmented –

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors

2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies

2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs

3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications

4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

What Market Trends Are Affecting The Next Generation Immunotherapies Market?

Leading companies in the next-generation immunotherapies market are concentrating on developing innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is an immunotherapy technique where a patient’s T cells, a type of immune cell, are genetically modified to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India’s first CAR T-cell therapy. This therapy, aimed at adult B-cell non-Hodgkin lymphoma, functions by genetically altering a patient’s immune cells to target and eradicate cancer cells, providing a highly effective and personalized treatment option. It offers new hope to patients for whom conventional therapies have failed, with the added benefit of being more affordable than similar global alternatives.

Who Are The Companies Operating Across The Next Generation Immunotherapies Market Value Chain?

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

Get The Full Next Generation Immunotherapies Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

Which Region Is The Top Contributor To The Next Generation Immunotherapies Market By Share?

North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Next Generation Immunotherapies Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Breast Cancer Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Oncology Companion Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the next generation immunotherapies market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Next Generation Immunotherapies Market from 2026 to 2030?

The market size for next generation immunotherapies has expanded quickly in recent years. Its value is expected to increase from $150.12 billion in 2025 to $168.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. This historical expansion can be linked to factors like the increasing global incidence of cancer, the initial positive outcomes from immune checkpoint inhibitors, enhanced investments in oncology research and development, regulatory endorsements for monoclonal antibodies, and a heightened understanding of immuno-oncology treatments.

The next generation immunotherapies market size is anticipated to undergo rapid expansion over the next few years. It is projected to climb to $262.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. The projected increase in this period is driven by advancements in next-generation antibody engineering, the expansion of applications beyond oncology, a rise in the approval of ADC-based therapies, the growing use of biomarker-driven treatment selection, and an increasing need for durable and long-lasting treatments. Prominent trends for the forecast period involve the broadening of combination immunotherapy regimens, the development of personalized cancer vaccines, the increasing adoption of bispecific antibodies, a stronger emphasis on reducing immune-related adverse events, and accelerated clinical trial activities for solid tumors.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

What Drivers Are Affecting Demand In The Next Generation Immunotherapies Market?

The expanding occurrence of cancer is anticipated to fuel the expansion of the next-generation immunotherapies market moving ahead. This condition encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. Its widespread nature stems from elements like an aging demographic, shifts in lifestyle, environmental influences, and more effective diagnostic techniques. These cutting-edge immunotherapies offer sophisticated, targeted therapies designed to boost the body’s defensive reaction against cancer, delivering superior efficacy, lasting results, and tailored approaches. As an illustration, projections released by Cancer Research UK, a UK-based cancer charity, indicate that by July 2024, cancer incidence rates across the United Kingdom are foreseen to rise for a majority of types between the periods 2023-2025 and 2038-2040, showing increases from less than 1% for breast cancer up to 50% for eye cancer. Conversely, a limited number of cancer types are predicted to decrease, with declines varying from 2% for lung cancer to 27% for mesothelioma. Consequently, the rising incidence of cancer is propelling the growth of the next-generation immunotherapies market.

Which Segment Groups Are Influencing The Next Generation Immunotherapies Market?

The next generation immunotherapies market covered in this report is segmented –

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors

2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies

2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs

3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications

4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

What Long-Term Trends Are Expected To Shape The Future Of The Next Generation Immunotherapies Market?

Leading companies active in the next-generation immunotherapies market are concentrating on developing innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy functions by genetically engineering a patient’s T cells, a type of immune cell, to express chimeric antigen receptors (CARs). For example, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India’s first CAR T-cell therapy. This particular therapy targets adult B-cell non-Hodgkin lymphoma by genetically modifying a patient’s immune cells to specifically identify and eradicate cancer cells, thereby presenting a highly effective and personalized treatment choice. It extends renewed optimism to patients for whom traditional treatments have failed, possessing the advantage of being more economically viable than comparable global alternatives.

Who Are The Primary Competitors In The Global Next Generation Immunotherapies Market?

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

Which Regions Are Poised For Strategic Growth In The Next Generation Immunotherapies Market?

North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Next Generation Immunotherapies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp

Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2026, By The Business Research Company

Natural Immune Booster Market Report 2026

https://www.thebusinessresearchcompany.com/report/natural-immune-booster-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Next Generation Immunotherapies Market Evolve From 2026 To 2030?

The next generation immunotherapies market has seen swift expansion in recent years. It is anticipated to expand from $150.12 billion in 2025 to $168.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. The increase observed in the past can be attributed to the rising global incidence of cancer, the early triumphs of immune checkpoint inhibitors, increased research and development investments in oncology, regulatory clearances for monoclonal antibodies, and a growing understanding of immuno-oncology treatments.

The market size for next generation immunotherapies is projected to experience substantial expansion over the upcoming years. This market is set to reach $262.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. Several factors during the forecast period are contributing to this growth, such as developments in next-generation antibody engineering, the widening scope of applications beyond cancer treatment, an increase in approvals for ADC-based therapies, the rise in biomarker-guided treatment choices, and a heightened need for effective and enduring therapies. Key trends anticipated during this period encompass the broadening of combination immunotherapy approaches, an increase in personalized cancer vaccines, the growing acceptance of bispecific antibodies, a greater emphasis on mitigating immune-related adverse effects, and accelerated clinical trial initiatives for solid tumors.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

What Key Drivers Are Influencing The Growth Of The Next Generation Immunotherapies Market?

The rising prevalence of cancer is projected to stimulate the expansion of the next-generation immunotherapies market in the future. Cancer refers to a group of diseases typified by the uncontrolled multiplication and spread of abnormal cells throughout the body. The increasing occurrence of cancer is attributed to factors such as aging populations, changes in lifestyle, environmental exposures, and more effective detection methods. Next-generation immunotherapies offer advanced, targeted treatments that strengthen the body’s immune system to combat cancer, leading to enhanced effectiveness, durability, and personalized care. For instance, in July 2024, according to projections published by Cancer Research UK, a UK-based cancer charity, cancer incidence rates in the United Kingdom are projected to increase for most types between 2023-2025 and 2038-2040, with rises ranging from less than 1% for breast cancer to 50% for eye cancer, while a smaller number of cancers are expected to see a decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Therefore, the growing prevalence of cancer is fueling the growth of the next-generation immunotherapies market.

Which Segment Areas Are Covered In The Next Generation Immunotherapies Market Analysis?

The next generation immunotherapies market covered in this report is segmented –

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors

2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies

2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs

3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications

4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

How Are Trends Impacting The Next Generation Immunotherapies Market?

Leading firms within the next-generation immunotherapies market are concentrating on creating advanced treatments, including CAR T-cell therapy, for conditions like cancers, autoimmune diseases, and infectious diseases. This immunotherapy involves genetically engineering a patient’s T cells, which are immune cells, to carry chimeric antigen receptors (CARs). A notable example occurred in January 2025, when Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, recognized as India’s first CAR T-cell therapy. Intended for adult B-cell non-Hodgkin lymphoma, this treatment modifies a patient’s immune cells genetically to specifically target and eliminate cancer cells, providing a very effective and customized therapeutic choice. It offers fresh promise to patients unresponsive to standard treatments, with the added benefit of being more cost-effective compared to comparable international alternatives.

Which Global Companies Are Actively Competing In The Next Generation Immunotherapies Market?

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

Read the full next generation immunotherapies market report here:

https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Next Generation Immunotherapies Market?

North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next Generation Immunotherapies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp

Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Breast Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Oncology Companion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model